Search results
New study involving nearly 185,000 patients recommends strengthening immunity against COVID-19 in...
Medical Xpress· 5 days agoThe research, published in the journal Nature Communications, recommends administering additional doses of the vaccine among this risk population. Cancer patients are at increased ...
Scientists argue over the origins of COVID-19 before U.S. Senate panel
New Hampshire Bulletin via Yahoo News· 5 days agoWASHINGTON – Scientists debated the origins of COVID-19 on Tuesday, trading barbs over whether the...
Scientists argue over the origins of COVID-19 before U.S. Senate panel
Iowa Capital Dispatch via Yahoo News· 5 days agoWASHINGTON — Scientists debated the origins of COVID-19 this week, trading barbs over whether the...
Long COVID Risk Factors Revealed In Data From Nearly 5,000 People
IFLScience· 7 days agoLong COVID describes a chronic condition that is present for at least three months after an...
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines | Investing.com
Investing.com· 7 days agoStocks Analysis by MarketBeat.com (Jea Yu) covering: Merck & Company Inc, Amgen Inc, Biogen Inc,...
SF wastewater levels show spike in COVID-19
The San Francisco Examiner· 6 days ago“In summer 2023, we saw wastewater concentrations for SARS-CoV-2 start to increase in mid-June and peak during August,” she told The ...
A study conducted by IDIAPJGol and ISGlobal recommends enhancing immunity against COVID-19 in cancer...
Hardwood Paroxysm· 3 days agoWork that has just been published in the journal Nature CommunicationsIt recommends administering...
Moderna shares rise as Argus lifts price target to $150 By Investing.com
Investing.com· 4 days agoThe firm's decision follows the U.S. Food and Drug Administration's (FDA) approval of Moderna's...
The COVID KP.3 Variant Makes Up 25% of U.S. Cases: Can Rapid Tests Detect It?
AOL· 3 days agoExperts said there’s no reason to believe KP.3 is causing any new symptoms of SARS-CoV-2, the virus that causes COVID ...
...NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation...
NewMediaWire via Yahoo Finance· 6 days ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, ...